Mithra Reports Full Year 2019 Financial Results

  • Record revenue (EUR 96.5 million) and EBITDA (EUR 40.7 million) increased respectively by 47% and 6%, mainly driven by U.S. deal for Estelle®
  • Anticipated future licensing milestones for Estelle® of EUR 322 million (out of a total of EUR 486 million)
  • Net loss significantly reduced to EUR 26.6 million (EUR 89.7 million in June 2019) thanks to successful earnout renegotiation and landmark deal with Mayne Pharma for Estelle®
  • Strengthening of book equity to EUR 163.3 million thanks to earnout renegotiation
  • Continued good cash management with comfortable level of cash at year-end
  • Key milestones achieved for environmental-friendly E4-based portfolio pipeline, with successful launch of Phase III study of Donesta® in menopause and regulatory submission of Estelle® in Europe
  • Valuation of business entity for clinical development projects based on E4 in 2020


Liege, Belgium, 09 March 2020 – 7:30  CET
– Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its financial results for the year ended 31 December 2019, prepared in accordance with IFRS.

Mithra to Host Webcast for Announcement 2019 Financial Results on 9 March 2020

Liege, Belgium, 05 March 2020 – 17:45  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it will host a live webcast on Monday 9 March 2020 at 15:00 CET/ 09:00 EST to announce its 2019 financial and operating results.

Mithra Receives acceptance of Marketing Authorization Application (MAA) to market Estelle® in Belgium and Luxembourg

Liege, Belgium, 03 March 2020 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the European Medicines Agency (EMA) has accepted its regulatory submission to market Estelle® in Belgium and Luxembourg.  Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate, containing 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP).